NCT05126433: A reported trial by Jazz Pharmaceuticals
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05126433 |
|---|---|
| Title | EMERGE-201: A Phase 2, Multicenter, Open-label Study of Lurbinectedin Efficacy and Safety in Participants With Advanced or Metastatic Solid Tumors |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 3, 2022 |
| Completion date | Dec. 20, 2023 |
| Required reporting date | Dec. 19, 2024, midnight |
| Actual reporting date | Dec. 19, 2024 |
| Date last checked at ClinicalTrials.gov | May 19, 2026 |
| Days late | None |